- Deaths from opioid painkiller overdoses increased by 400% among women between 1999 and 2010, CDC says
- Egalet, Shionogi to develop abuse-deterrent opioids
- Homeopathy, returning brands shape pain relief
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- FDA issues sweeping new requirements for long-acting opioids
NEWARK, Calif. — Depomed has launched a new drug for breakthrough pain in cancer patients, the company said Monday.
The drug maker announced the launch of Lazanda (fentanyl) nasal spray, meant for treating adults who are taking opioid painkillers, but have become tolerant to them. The company also have launched a Signature Support Program designed to streamline patient access to the drug, including reimbursement and co-pay assistance. Other benefits of the program include prescription reminders and eligibility for one month's supply for free.
"Breakthrough pain is very common among cancer patients and can be properly managed to reduce the number and severity of episodes and the interference of daily activities," University of Arizona anesthesiology professor Emil Annabi said. "Studies show that breakthrough pain is associated with poorer function and higher cost of care, which is why cancer patients need support services so they can focus on getting pain relief and not be troubled by reimbursement and access issues."